401 related articles for article (PubMed ID: 25269479)
1. ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
Jossé R; Martin SE; Guha R; Ormanoglu P; Pfister TD; Reaper PM; Barnes CS; Jones J; Charlton P; Pollard JR; Morris J; Doroshow JH; Pommier Y
Cancer Res; 2014 Dec; 74(23):6968-79. PubMed ID: 25269479
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes.
Furuta T; Takemura H; Liao ZY; Aune GJ; Redon C; Sedelnikova OA; Pilch DR; Rogakou EP; Celeste A; Chen HT; Nussenzweig A; Aladjem MI; Bonner WM; Pommier Y
J Biol Chem; 2003 May; 278(22):20303-12. PubMed ID: 12660252
[TBL] [Abstract][Full Text] [Related]
3. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
Huntoon CJ; Flatten KS; Wahner Hendrickson AE; Huehls AM; Sutor SL; Kaufmann SH; Karnitz LM
Cancer Res; 2013 Jun; 73(12):3683-91. PubMed ID: 23548269
[TBL] [Abstract][Full Text] [Related]
4. ZEB1 inhibition sensitizes cells to the ATR inhibitor VE-821 by abrogating epithelial-mesenchymal transition and enhancing DNA damage.
Song N; Jing W; Li C; Bai M; Cheng Y; Li H; Hou K; Li Y; Wang K; Li Z; Liu Y; Qu X; Che X
Cell Cycle; 2018; 17(5):595-604. PubMed ID: 29157079
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor AZD7762.
Aris SM; Pommier Y
Cancer Res; 2012 Feb; 72(4):979-89. PubMed ID: 22189968
[TBL] [Abstract][Full Text] [Related]
6. Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide.
Zhao H; Rybak P; Dobrucki J; Traganos F; Darzynkiewicz Z
Cytometry A; 2012 Jan; 81(1):45-51. PubMed ID: 22140093
[TBL] [Abstract][Full Text] [Related]
7. BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.
Coussy F; El-Botty R; Château-Joubert S; Dahmani A; Montaudon E; Leboucher S; Morisset L; Painsec P; Sourd L; Huguet L; Nemati F; Servely JL; Larcher T; Vacher S; Briaux A; Reyes C; La Rosa P; Lucotte G; Popova T; Foidart P; Sounni NE; Noel A; Decaudin D; Fuhrmann L; Salomon A; Reyal F; Mueller C; Ter Brugge P; Jonkers J; Poupon MF; Stern MH; Bièche I; Pommier Y; Marangoni E
Sci Transl Med; 2020 Feb; 12(531):. PubMed ID: 32075943
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylation of BLM, dissociation from topoisomerase IIIalpha, and colocalization with gamma-H2AX after topoisomerase I-induced replication damage.
Rao VA; Fan AM; Meng L; Doe CF; North PS; Hickson ID; Pommier Y
Mol Cell Biol; 2005 Oct; 25(20):8925-37. PubMed ID: 16199871
[TBL] [Abstract][Full Text] [Related]
9. Tipin functions in the protection against topoisomerase I inhibitor.
Hosono Y; Abe T; Higuchi M; Kajii K; Sakuraba S; Tada S; Enomoto T; Seki M
J Biol Chem; 2014 Apr; 289(16):11374-11384. PubMed ID: 24573676
[TBL] [Abstract][Full Text] [Related]
10. Small-molecule inhibitors of Ataxia Telangiectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation.
Biskup E; Naym DG; Gniadecki R
J Dermatol Sci; 2016 Dec; 84(3):239-247. PubMed ID: 27743911
[TBL] [Abstract][Full Text] [Related]
11. Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.
Sanjiv K; Hagenkort A; Calderón-Montaño JM; Koolmeister T; Reaper PM; Mortusewicz O; Jacques SA; Kuiper RV; Schultz N; Scobie M; Charlton PA; Pollard JR; Berglund UW; Altun M; Helleday T
Cell Rep; 2016 Jan; 14(2):298-309. PubMed ID: 26748709
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.
Tomicic MT; Kaina B
Biochim Biophys Acta; 2013 Jan; 1835(1):11-27. PubMed ID: 23006513
[TBL] [Abstract][Full Text] [Related]
13. WRN helicase regulates the ATR-CHK1-induced S-phase checkpoint pathway in response to topoisomerase-I-DNA covalent complexes.
Patro BS; Frøhlich R; Bohr VA; Stevnsner T
J Cell Sci; 2011 Dec; 124(Pt 23):3967-79. PubMed ID: 22159421
[TBL] [Abstract][Full Text] [Related]
14. New Topoisomerase I mutations are associated with resistance to camptothecin.
Gongora C; Vezzio-Vie N; Tuduri S; Denis V; Causse A; Auzanneau C; Collod-Beroud G; Coquelle A; Pasero P; Pourquier P; Martineau P; Del Rio M
Mol Cancer; 2011 May; 10():64. PubMed ID: 21619602
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Massey AJ
Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
[TBL] [Abstract][Full Text] [Related]
16. The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons.
Flatten K; Dai NT; Vroman BT; Loegering D; Erlichman C; Karnitz LM; Kaufmann SH
J Biol Chem; 2005 Apr; 280(14):14349-55. PubMed ID: 15699047
[TBL] [Abstract][Full Text] [Related]
17. ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation.
Gomes LR; Rocha CRR; Martins DJ; Fiore APZP; Kinker GS; Bruni-Cardoso A; Menck CFM
Cell Death Dis; 2019 Jun; 10(6):459. PubMed ID: 31189884
[TBL] [Abstract][Full Text] [Related]
18. Gli1 protein regulates the S-phase checkpoint in tumor cells via Bid protein, and its inhibition sensitizes to DNA topoisomerase 1 inhibitors.
Tripathi K; Mani C; Barnett R; Nalluri S; Bachaboina L; Rocconi RP; Athar M; Owen LB; Palle K
J Biol Chem; 2014 Nov; 289(45):31513-25. PubMed ID: 25253693
[TBL] [Abstract][Full Text] [Related]
19. TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor.
Jo U; Murai Y; Agama KK; Sun Y; Saha LK; Yang X; Arakawa Y; Gayle S; Jones K; Paralkar V; Sundaram RK; Van Doorn J; Vasquez JC; Bindra RS; Choi WS; Pommier Y
Mol Cancer Ther; 2022 Jul; 21(7):1090-1102. PubMed ID: 35439320
[TBL] [Abstract][Full Text] [Related]
20. Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response.
Zhang YW; Jones TL; Martin SE; Caplen NJ; Pommier Y
J Biol Chem; 2009 Jul; 284(27):18085-95. PubMed ID: 19416980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]